World Cancer Day is an international day marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. Cancer is the leading cause of disease-related death among working-age adults in high-income and middl…
“You have cancer.”These three words have the power to alter the course of one’s life – whether they’re receiving the news, or divulging the information to a loved one. A cancer diagnosis can be difficult to process, and for many, the diagnosis and corr…
Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements existing Sandoz portfolio and consists primarily of o…
New Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1 Label update provides clinicians with greater choice for their patients, based on clinical response…
Download the media releaseEnglish (PDF 0.1 MB ) | Deutsch (PDF 0.1 MB) | Français (PDF 0.1 MB)Condensed financial report (PDF 0.7 MB) …
Full year net sales for continuing operations1 up 9% (cc2, +6% USD):Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million Oncology BU growing 10% (cc) driven b…
Planting a Better FutureNovartis CEO Vas Narasimhan moderated a panel of some of the youngest leaders to discuss which actions should leaders prioritize to secure prosperity for the next generation.Watch the sessionI have the privilege of moderating a …
Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who,…
This conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.Novartis CE…
Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly higher affinity than current standard of care Xolair (omalizumab)1 The study published in Nature Communications suggests lige…